Certara Sells Regulatory and Medical Writing Business to Veristat for Up to $135M
Certara (NASDAQ:CERT) has agreed to sell its regulatory and medical writing business to Veristat for up to $135 million, expected to close in Q2 2026. The unit generated $50 million in revenue and $17 million in adjusted EBITDA in 2025.
Topics: business sale Certara medical writing regulatory writing Veristat